Literature DB >> 8632720

Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide.

J J Piotrowski1, S Shah, J J Alexander.   

Abstract

The initial stage of atherosclerotic plaque formation involves oxidation of the phosphatidyl-choline moiety of low density lipoprotein (LDL) and subsequent uptake by macrophages. Ongoing uptake in developing plaque also may involve oxidized LDL and would require an oxidizing environment in plaque lipids. Atherosclerotic plaque lipids from 12 patients undergoing peripheral vascular procedures were extracted in chloroform: methanol (2:1). This extract was applied to a 25 cm 5 micron silica HPLC column and eluted with a ternary gradient mobile phase utilizing a laser light scattering (ELSD) mass detector. Individual lipid fractions were then analyzed. Cholesterol, both free and esterified, was the most prominent lipid in plaque (104 +/- 74 mg/gm tissue. However, lipid peroxides were present in much higher concentrations (3.52 +/- 2.84 FU X 10(4)/mg phospholipid) and overall level (21.27 +/- 10.10 FU X 10(4)/gm plaque) in the phospholipid component (*p< 0.05). Phosphatidyl-choline (PC) accounted for 63% of the total phospholipid peroxides recovered (6.31 +/- 5.09 mg/gm plaque; *p<0.05). PC and phosphatidylinositol (PI) content were linearly related to lipid peroxide fluorescence (PC; r=0.696; p=0.01) (PI; r=0.809; p=0.001). Lipid peroxides in human atherosclerotic plaque are present primarily in the phospholipid component and phosphatidyl-choline forms the bulk of these peroxides. PC may play an important role in ongoing plaque lipid accumulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632720     DOI: 10.1016/0024-3205(95)02351-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans.

Authors:  Amir Ravandi; Gregor Leibundgut; Ming-Yow Hung; Mitul Patel; Patrick M Hutchins; Robert C Murphy; Anand Prasad; Ehtisham Mahmud; Yury I Miller; Edward A Dennis; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2014-03-05       Impact factor: 24.094

Review 2.  Nature and nurture in atherosclerosis: The roles of acylcarnitine and cell membrane-fatty acid intermediates.

Authors:  Harry C Blair; Jorge Sepulveda; Dionysios J Papachristou
Journal:  Vascul Pharmacol       Date:  2015-06-30       Impact factor: 5.773

Review 3.  Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions.

Authors:  Karen Briley-Saebo; Calvin Yeang; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Cardiovasc Transl Res       Date:  2014-10-09       Impact factor: 4.132

4.  Phospholipids and oxophospholipids in atherosclerotic plaques at different stages of plaque development.

Authors:  Amir Ravandi; Saeid Babaei; Ramsey Leung; Juan Carlos Monge; George Hoppe; Henry Hoff; Hiroshi Kamido; Arnis Kuksis
Journal:  Lipids       Date:  2004-02       Impact factor: 1.880

5.  Phosphatidylcholine hydroperoxide-induced THP-1 cell adhesion to intracellular adhesion molecule-1.

Authors:  Akira Asai; Fumitaka Okajima; Kiyotaka Nakagawa; Daigo Ibusuki; Kyoko Tanimura; Yasushi Nakajima; Mototsugu Nagao; Mariko Sudo; Taro Harada; Teruo Miyazawa; Shinichi Oikawa
Journal:  J Lipid Res       Date:  2008-12-29       Impact factor: 5.922

Review 6.  Nutrients, Nutraceuticals, and Xenobiotics Affecting Renal Health.

Authors:  Carmela Cosola; Alice Sabatino; Ighli di Bari; Enrico Fiaccadori; Loreto Gesualdo
Journal:  Nutrients       Date:  2018-06-23       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.